Overview

• MaxCyte Q3 total revenue of $6.8 mln missed analyst expectations

• Core business revenue declined 21% yr/yr to $6.4 mln

• Company maintains $158 mln in cash and investments as of Q3 2025

Outlook

• MaxCyte reiterates 2025 core revenue guidance as flat to a 10% decline

• SPL Program-related revenue expected to be $5 mln for 2025

• MaxCyte expects 2025 year-end cash between $152 mln and $155 mln

Result Drivers

• SPL PROGRAM GROWTH - SPL Program-related revenue increased significantly, contributing to total revenue

• NEW SPL CLIENTS - MaxCyte added new SPL clients, including Moonlight Bio, Adicet Bio, and Anocca AB, increasing total SPL agreements to 32

• GROSS MARGIN STRENGTH - Gross margin remains strong at 77%, with a non-GAAP adjusted gross margin of 81%

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for MaxCyte Inc is $5.72, about 71.9% above its November 4 closing price of $1.61

Press Release: ID:nGNXczkJq

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)